Journal of Applied Physiology  AJP: Regulatory, Integrative and Comparative Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Appl Physiol 88: 1571-1575, 2000;
8750-7587/00 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (64)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rankinen, T.
Right arrow Articles by Bouchard, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rankinen, T.
Right arrow Articles by Bouchard, C.
Vol. 88, Issue 5, 1571-1575, May 2000

No association between the angiotensin-converting enzyme ID polymorphism and elite endurance athlete status

Tuomo Rankinen1, Bernd Wolfarth2, Jean-Aimé Simoneaudagger ,3, Dirk Maier-Lenz2, Rainer Rauramaa4, Miguel A. Rivera5, Marcel R. Boulay3, Yvon C. Chagnon3, Louis Pérusse3, Joseph Keul2, and Claude Bouchard1

1 Pennington Biomedical Research Center, Human Genomics Laboratory, Baton Rouge, Louisiana 70808-4124; 2 Department of Prevention, Rehabilitation, and Sports Medicine, University of Freiburg, 79106 Freiburg, Germany; 3 Physical Activity Sciences Laboratory, Laval University, Ste-Foy, Québec G1K 7P4; Canada; 4 Kuopio Research Institute of Exercise Medicine, Department of Physiology, University of Kuopio, and Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, 70100 Kuopio, Finland; and 5 Department of Physiology and Department of Physical Medicine, Rehabilitation, and Sports Medicine, University of Puerto Rico School of Medicine, San Juan, Puerto Rico 00936


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Several studies have reported that the insertion (I) allele of the angiotensin-converting enzyme (ACE) I/deletion (D) polymorphism is associated with enhanced responsiveness to endurance training and is more common in endurance athletes than in sedentary controls. We tested the latter hypothesis in a cohort of 192 male endurance athletes with maximal oxygen uptake >= 75 ml · kg-1 · min-1 and 189 sedentary male controls. The ACE ID polymorphism in intron 16 was typed with the three-primer polymerase chain reaction method. Both the genotype (P = 0.214) and allele (P = 0.095) frequencies were similar in the athletes and the controls. Further analyses in the athletes revealed no excess of the I allele among the athletes within the highest quartile (> 80 ml · kg-1 · min-1) or decile (>83 ml · kg-1 · min-1) of maximal oxygen uptake. These data from the GENATHLETE cohort do not support the hypothesis that the ACE ID polymorphism is associated with a higher cardiorespiratory endurance performance level.

genetics; sports; endurance performance; insertion/deletion


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

PERFORMANCE IN ENDURANCE SPORTS is a multifactorial phenotype, influenced by several factors, such as physique, biomechanical, physiological, metabolic, behavioral, psychological, and social characteristics. The effects of environmental factors on endurance performance are well documented, but a considerable amount of data from twin and family studies have shown that cardiorespiratory fitness, for which maximal oxygen consumption (VO2 max) is traditionally recognized as the gold standard, is also influenced by genetic factors. For instance, in pairs of monozygotic twins, the VO2 max response to standardized training programs in a series of experiments was characterized by six to nine times more variance between genotypes (between pairs of twins) than within genotypes (within pairs of twins) (6). Similarly, in the sedentary state, the intrapair resemblance for cardiorespiratory endurance phenotypes has been significantly higher in monozygotic twins than in dizygotic twins, with heritability estimates ranging from 25 to 66% (7, 11, 21, 40). Family studies have suggested a genetic effect of ~25-40% for VO2 max adjusted for age, gender, and body mass or body composition (18, 20, 25). In the HERITAGE Family Study cohort, maximal heritabilities of 51 and 47% were observed for the VO2 max in the sedentary state (5) and its response to 20 wk of endurance training (4), respectively.

Because of the polygenic nature of endurance performance phenotypes, it is unlikely that the genetic component of these traits will be explained by DNA sequence variation at only a few genes. It is more likely that several gene loci, each with a small but significant contribution, will be responsible for this genetic component. A limited number of candidate genes have been tested so far in this context. For example, data from the HERITAGE Family Study have revealed statistically significant associations between the training responses of cardiorespiratory fitness-related phenotypes and skeletal muscle-specific creatine kinase and Na+-K+-ATPase alpha 2 gene polymorphisms (29, 33, 34).

Over the past 2 yr, some studies have suggested that the DNA sequence variation at the gene locus encoding angiotensin-converting enzyme (ACE) is associated with physical performance. A series of papers based on a cohort of British military recruits have found that the insertion (I) allele and the II genotype of the I/deletion (D) polymorphism in intron 16 of the ACE gene were associated with a lower training-induced cardiac hypertrophy (23) and greater increases in performance after a 10-wk physical training program (22, 24). A higher frequency of the I allele and the II genotype was reported in Australian rowers (12) and British mountaineers (24) than in sedentary controls. In a small group of postmenopausal women, the homozygotes for the I allele had higher VO2 max than did the other genotypes (13). In British Olympic-standard runners, an increase in frequency of the I allele as a function of distance run was reported, although the association disappeared when the analysis was repeated only in Caucasian athletes (26).

However, in a cohort of 724 sedentary subjects from the HERITAGE Family Study, we found no support for the hypothesis that the ACE I allele was associated with a greater trainability of fitness-related phenotypes (30). Both in blacks (n = 248) and in Caucasians (n = 476), all of the 26 phenotypes measured in the sedentary state were similar across the ACE ID genotypes. Of the training response phenotypes, statistically significant associations were found only in Caucasian offsprings, but in sharp contrast to previous studies, the DD homozygotes showed greater increases in oxygen consumption and power output phenotypes than did the other genotypes. Moreover, in the HERITAGE Family Study, a genomic scan for VO2 max in the sedentary state and in its response to training provided no evidence of linkage with the ACE gene locus or any other regions on chromosome 17 (8). Similarly, in a group of 120 Australian endurance athletes (41) and a cohort of 404 British Olympic-standard athletes (26), the ACE ID genotype and allele frequencies did not differ from those of sedentary control groups. In a cohort of 80 Finnish endurance athletes, frequencies of the II, ID, and DD genotypes were 0.225, 0.475 and 0.300, respectively, i.e., identical to the frequencies reported in general population (14, 16).

Because the previous positive findings have emerged mainly from studies with relatively small sample sizes, and because the results derived from sedentary subjects may not necessarily reflect the situation in highly trained athletes, we investigated whether the ACE ID polymorphism was associated with endurance athlete status in the GENATHLETE cohort comprising 192 elite endurance athletes and 189 sedentary controls.


    METHODS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Subjects. Altogether, 192 male endurance athletes with a VO2 max of at least 75 ml · kg-1 · min-1 [mean 78.6 ± 3.2 (SD) ml · kg-1 · min-1, range 75.0-92.9 ml · kg-1 · min-1] and 189 sedentary male controls [VO2 max 36.4 ± 7.4 (SD) ml · kg-1 · min-1, range 23.1-50.0 ml · kg-1 · min-1] were available for the present study. The athletes were recruited from Canada (n = 51), Germany (n = 63), Finland (n = 42), and the United States (n = 36), and they represented the following endurance sports: cross-country skiing (n = 59), biathlon (n = 40), nordic combined (n = 2), long-distance running (n = 20), middle-distance running (n = 19), and road cycling (n = 48). All the athletes had been competing at the national or international level for several years. The control group comprised healthy sedentary subjects from the same geographic areas as the athletes. The controls either were derived from the previous studies performed in our laboratories (3, 31) or were recruited specifically for the GENATHLETE study (Germany). The number of athletes and controls from each country was approximately equal. All the subjects were Caucasians. Informed written consent was obtained from all subjects.

The VO2 max of the athletes was determined in the course of incremental exercise tests on cycle ergometers (cyclists) or motor-driven treadmills (skiers and runners) when the athletes were at their peak. The VO2 max of the controls was assessed during an incremental cycle ergometer test.

Genotype determinations. Genomic DNA was isolated from lymphoblastoid cell lines or white blood cells following a standard protocol (37). The ACE ID polymorphism was typed with a PCR-based method using three primers as previously described (10). The final reaction mixture of 15 µl contained 100 ng of genomic DNA, 3.0 mM MgCl2, 200 µM each 2'deoxynucleoside 5'-triphosphates, 300 nM primers flanking the insertion sequence, 140 nM nested primer, 4.7% DMSO, and 1.0 U of Taq polymerase (Pharmacia Biotech, Baie d'Urfé, PQ). The PCR protocol (model 9600 thermal cycler, Perkin Elmer, Norwalk, CT) consisted of one cycle at 94°C for 3 min, 55°C for 1 min, and 72°C for 1 min, followed by 35 cycles at 94°C for 30 s, 55°C for 30 s, 72°C for 45 s, and finally 1 cycle at 72°C for 10 min. The PCR products were separated on 3.5% agarose gel and visualized under ultraviolet light after ethidium bromide staining.

Statistical methods. All statistical analyses were done with the version 6.12 of the SAS statistical software package (SAS Institute, Cary, NC). A chi 2 test was used to confirm that the observed genotype frequencies were in a Hardy-Weinberg equilibrium and to compare the ACE ID allele and genotype frequencies between athletes and controls, as well as between different sports and places of origin. Differences in VO2 max, body weight, and height among the athletes from different sports were tested with an analysis of variance by using the general linear model procedure of the SAS package.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Among the athletes, VO2 max and height were similar across sports (P = 0.246 and 0.715, respectively) and places of origin (P = 0.682 and 0.057, respectively), whereas skiers and cyclists were heavier than runners [70.8 ± 0.7 (SE) and 71.0 ± 1.2 vs. 64.7 ± 1.3 kg, respectively; P = 0.0002]. However, the ACE ID genotype frequencies did not differ among the sports, with values of 0.248, 0.495, and 0.257 in skiers, 0.256, 0.436 and 0.308 in runners, and 0.292, 0.438, and 0.271 in cyclists for the II, ID, and DD genotypes, respectively (chi 2 = 0.85, df = 4, P = 0.932). The genotype frequencies were also similar across countries of origin for both athletes and controls (0.223, 0.417, and 0.360 in Canada, 0.262, 0.469, and 0.269 in Germany, 0.184, 0.513, and 0.303 in Finland, and 0.250, 0.583, and 0.167 in the United States for the II, ID, and DD, genotypes, respectively; chi 2 = 7.66, df = 6, P = 0.264).

No differences were observed in the allele and genotype frequencies of the ACE ID polymorphism between athletes and controls (Table 1). In both groups, the genotype frequencies were in Hardy-Weinberg equilibrium. The GENATHLETE study has been designed as a case-control study, but because some previous studies have reported that the ACE I allele was associated with a high performance level, we tested whether a similar trend was present among our endurance athletes. For this purpose, two VO2 max cutoffs were used to classify the athletes: 80 ml · kg-1 · min-1 represented a cutoff for the highest VO2 max quartile (n = 52), and 83 ml · kg-1 · min-1 was used to define the highest decile of VO2 max (n = 23). With both cutoffs, we found no evidence for the accumulation of the I allele or the II genotype among the athletes with the highest VO2 max values. The frequencies of the II, ID, and DD genotypes, respectively, were 0.327, 0.385, and 0.288 in the highest quartile and were 0.261, 0.391, and 0.348 in the highest decile (Fig. 1), i.e., similar to those observed in the athletes with a lower VO2 max.

                              
View this table:
[in this window]
[in a new window]
 
Table 1.   Allele and genotype frequencies of the ACE ID polymorphism in elite endurance athletes and sedentary controls



View larger version (30K):
[in this window]
[in a new window]
 
Fig. 1.   Angiotensin-converting enzyme (ACE) insertion (I)/deletion (D) genotype frequencies in the athletes according to VO2 max levels. No. of athletes is indicated within each bar. chi 2 = 2.48, df = 4, P = 0.648.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

The results of the present study do not support the hypothesis that variation in the ACE gene locus has an influence on human cardiorespiratory endurance performance. The seemingly controversial results reported thus far may be due to factors related to sample sizes, study designs, and phenotype measurements. The positive findings have emerged from relatively small cohorts (n from 25 to 91), whereas studies with large number of subjects (n from 120 to 724) and rigorously controlled phenotype measurements and exercise training programs, such as the HERITAGE Family Study (30), the study by Taylor et al. (41), and the present study, have yielded negative results. A similar effect of sample size has been observed in the studies dealing with the associations between the ACE ID polymorphism and various cardiovascular disorders. The studies based on large numbers of subjects have generally failed to confirm the positive findings arising from smaller cohorts (1, 19, 39, 44). Moreover, two meta-analyses have detected a publication bias toward positive findings from smaller studies (36, 39), a finding that may also be relevant for the topic of the ACE genotype and physical performance.

Other relevant features of the previous studies are that the associations between the ACE ID polymorphism and physical performance were mainly tested post hoc (i.e., the studies were not originally designed to address such questions) and that the phenotypes were not well standardized. An exception is the study by Gayagay et al. (12) where the athletes were selected from a clearly defined group of Australian Olympic-level rowers. In the present study, instead of selecting a specific sport, we employed a preset VO2 max criterion that the athletes had to meet to be included in the study. We were not able to replicate the findings of Gayagay et al. One explanation for the different outcome may be that rowers represent a special group among endurance athletes. Rowing employs mainly upper body musculature, whereas the performance level in other endurance sports is mostly dependent on the function of the muscles of the lower body or both the lower and upper body. Another potential explanation could be the smaller sample size of rowers.

It has been suggested that the ACE I allele is associated with a high level of physical performance (24). Along the lines of this hypothesis we did a subgroup analysis in the elite endurance athletes group. Even in the athletes with VO2 max values over 83 ml · kg-1 · min-1 (highest decile), we found no trend for an excess of the I allele or a low number of DD homozygotes (Fig. 1). In our opinion, these findings argue against the idea that the ACE ID polymorphism is associated with extraordinary cardiorespiratory endurance performance. However, it remains to be confirmed whether the ACE ID polymorphism is specifically associated with an adaptation to perform at high altitude. In Native South Americans it does not seem to be the case (35), but similar data in Caucasians are still missing.

Although an association between the ACE ID genotype and circulating ACE levels has been established (32, 42), there are surprisingly few data on the physiological mechanisms for the proposed associations between the ACE ID polymorphism and the various phenotypes. Systemic angiotensin II levels and blood pressure seem to be unaffected by the ACE ID genotype-related variation in plasma ACE levels (17). In addition, treatment with ACE inhibitors causes a drastic decrease in ACE activity and angiotensin II levels but has no effect on endurance performance in healthy or mildly hypertensive subjects (2, 27, 28). It has been suggested that the greater ACE II genotype frequency in endurance athletes could reflect the selection of individuals with a "healthier" cardiovascular system and, thus a higher aerobic capacity (12, 24, 26). However, the results by Taylor et al. (41), our findings based on a large group of endurance athletes with documented high VO2 max level, and the controversial reports on the associations between the ACE ID genotype and various cardiovascular phenotypes cast doubts over this hypothesis. Nevertheless, it is possible that an interaction with other genetic, physiological, or environmental factors is required for the expression of the ACE ID genotype effects. This possibility is underlined by the finding that the influence of the ACE ID genotype on plasma angiotensin II levels is detected when the circulating substrate concentrations are increased by angiotensin I infusion (43).

In addition to the endurance performance traits, the data on the effects of the ACE ID polymorphism on various cardiovascular phenotypes in general are far from clear. The interpretation of the data is further complicated by the fact that even the studies with positive results have reported that the associations seemed to be restricted to a special subgroup of the cohort, such as subjects with low levels of cardiovascular risk factors (9). Moreover, the reports showing that, unlike one would assume, the D allele and DD genotype were more common in centenarians (38) and were associated with a lower risk of Alzheimer's disease (15) further add to the confusion. Thus it is obvious that more studies are needed to fully understand the function of the ACE gene and the possible effects of its DNA sequence variation on various biological traits.

In conclusion, the results from the GENATHLETE cohort do not support the hypothesis that the ACE ID genotype is a determinant of cardiorespiratory endurance performance.


    ACKNOWLEDGEMENTS

We acknowledge the inspiration and contributions to this paper of Jean-Aimé Simoneau, PhD, who died on August 27, 1999, after a prolonged illness.


    FOOTNOTES

dagger  Deceased 27 August 1999.

Thanks are expressed to Drs. N. Gledhill, G. Huber, E. Jacob, T. Noakes, G. Phillips, K. W. Rundell, H. K. Rusko, and J. Stray-Gundersen, who kindly provided some of the DNA samples from the athletes.

This work was supported by Fonds pour la Formation de Chercheurs et d'Aide à la Recherche Quebec Grant ER-2449 and National Sciences and Engineering Research Council of Canada Grant OPG-0042791.

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Address for reprint requests and other correspondence: C. Bouchard, Pennington Biomedical Research Center, 6400 Perkins Rd., Baton Rouge, LA 70808-4124. (E-mail: bouchac{at}pbrc.edu).

Received 21 October 1999; accepted in final form 18 December 1999.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

1.   Agerholm-Larsen, B, Nordestgaard BG, Steffensen R, Sorensen TI, Jensen G, and Tybjaerg-Hansen A. ACE gene polymorphism: ischemic heart disease and longevity in 10,150 individuals. A case-referent and retrospective cohort study based on the Copenhagen City Heart Study. Circulation 95: 2358-2367, 1997[Abstract/Free Full Text].

2.   Aldigier, JC, Huang H, Dalmay F, Lartigue M, Baussant T, Chassain AP, Leroux-Robert C, and Galen FX. Angiotensin-converting enzyme inhibition does not suppress plasma angiotensin II increase during exercise in humans. J Cardiovasc Pharmacol 21: 289-295, 1993[ISI][Medline].

3.   Bouchard, C. Genetic epidemiology, association and sib-pair linkage: results from the Quebec Family Study. In: Molecular and Genetic Aspects of Obesity, edited by Bray G A., and Ryan D. H.. Baton Rouge: Louisiana State Univ. Press, 1996, p. 470-481.

4.   Bouchard, C, An P, Rice T, Skinner JS, Wilmore JH, Gagnon J, Perusse L, Leon AS, and Rao DC. Familial aggregation of VO2 max response to exercise training: results from the HERITAGE Family Study. J Appl Physiol 87: 1003-1008, 1999[Abstract/Free Full Text].

5.   Bouchard, C, Daw EW, Rice T, Perusse L, Gagnon J, Province MA, Leon AS, Rao DC, Skinner JS, and Wilmore JH. Familial resemblance for VO2 max in the sedentary state: the HERITAGE family study. Med Sci Sports Exerc 30: 252-258, 1998[ISI][Medline].

6.   Bouchard, C, Dionne FT, Simoneau JA, and Boulay MR. Genetics of aerobic and anaerobic performances. Exerc Sport Sci Rev 20: 27-58, 1992[Medline].

7.   Bouchard, C, Lesage R, Lortie G, Simoneau JA, Hamel P, Boulay MR, Perusse L, Theriault G, and Leblanc C. Aerobic performance in brothers, dizygotic and monozygotic twins. Med Sci Sports Exerc 18: 639-646, 1986[ISI][Medline].

8.   Bouchard, C, Rankinen T, Chagnon YC, Rice T, Perusse L, Gagnon J, Borecki I, An P, Leon AS, Skinner JS, Wilmore JH, Province M, and Rao DC. Genomic scan for maximal oxygen uptake and its response to training in the HERITAGE Family Study. J Appl Physiol 88: 551-559, 2000[Abstract/Free Full Text].

9.   Cambien, F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, Tiret L, Amouyel P, Alhenc-Gelas F, and Soubrier F. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359: 641-644, 1992[Medline].

10.   Evans, AE, Poirier O, Kee F, Lecerf L, McCrum E, Falconer T, Crane J, O'Rourke DF, and Cambien F. Polymorphisms of the angiotensin-converting-enzyme gene in subjects who die from coronary heart disease. QJM 87: 211-214, 1994[Abstract/Free Full Text].

11.   Fagard, R, Bielen E, and Amery A. Heritability of aerobic power and anaerobic energy generation during exercise. J Appl Physiol 70: 357-362, 1991[Abstract/Free Full Text].

12.   Gayagay, G, Yu B, Hambly B, Boston T, Hahn A, Celermajer DS, and Trent RJ. Elite endurance athletes and the ACE I allele---the role of genes in athletic performance. Hum Genet 103: 48-50, 1998[ISI][Medline].

13.   Hagberg, JM, Ferrell RE, McCole SD, Wilund KR, and Moore GE. VO2 max is associated with ACE genotype in postmenopausal women. J Appl Physiol 85: 1842-1846, 1998[Abstract/Free Full Text].

14.   Karjalainen, J, Kujala UM, Stolt A, Mantysaari M, Viitasalo M, Kainulainen K, and Kontula K. Angiotensinogen gene M235T polymorphism predicts left ventricular hypertrophy in endurance athletes. J Am Coll Cardiol 34: 494-499, 1999[Abstract/Free Full Text].

15.   Kehoe, PG, Russ C, McIlory S, Williams H, Holmans P, Holmes C, Liolitsa D, Vahidassr D, Powell J, McGleenon B, Liddell M, Plomin R, Dynan K, Williams N, Neal J, Cairns NJ, Wilcock G, Passmore P, Lovestone S, Williams J, and Owen MJ. Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. Nat Genet 21: 71-72, 1999[ISI][Medline].

16.   Kiema, TR, Kauma H, Rantala AO, Lilja M, Reunanen A, Kesaniemi YA, and Savolainen MJ. Variation at the angiotensin-converting enzyme gene and angiotensinogen gene loci in relation to blood pressure. Hypertension 28: 1070-1075, 1996[Abstract/Free Full Text].

17.   Lachurie, ML, Azizi M, Guyene TT, Alhenc-Gelas F, and Menard J. Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects. Circulation 91: 2933-2942, 1995[Abstract/Free Full Text].

18.   Lesage, R, Simoneau JA, Jobin J, Leblanc J, and Bouchard C. Familial resemblance in maximal heart rate, blood lactate and aerobic power. Hum Hered 35: 182-189, 1985[ISI][Medline].

19.   Lindpaintner, K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, LaMotte F, Buring J, and Hennekens CH. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 332: 706-711, 1995[Abstract/Free Full Text].

20.   Lortie, G, Bouchard C, Leblanc C, Tremblay A, Simoneau JA, Theriault G, and Savoie JP. Familial similarity in aerobic power. Hum Biol 54: 801-812, 1982[ISI][Medline].

21.   Maes, HH, Beunen GP, Vlietinck RF, Neale MC, Thomis M, Vanden Eynde B, Lysens R, Simons J, Derom C, and Derom R. Inheritance of physical fitness in 10-yr-old twins and their parents. Med Sci Sports Exerc 28: 1479-1491, 1996[ISI][Medline].

22.   Montgomery, H, Clarkson P, Barnard M, Bell J, Brynes A, Dollery C, Hajnal J, Hemingway H, Mercer D, Jarman P, Marshall R, Prasad K, Rayson M, Saeed N, Talmud P, Thomas L, Jubb M, World M, and Humphries S. Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training. Lancet 353: 541-545, 1999[ISI][Medline].

23.   Montgomery, HE, Clarkson P, Dollery CM, Prasad K, Losi MA, Hemingway H, Statters D, Jubb M, Girvain M, Varnava A, World M, Deanfield J, Talmud P, McEwan JR, McKenna WJ, and Humphries S. Association of angiotensin-converting enzyme gene ID polymorphism with change in left ventricular mass in response to physical training. Circulation 96: 741-747, 1997[Abstract/Free Full Text].

24.   Montgomery, HE, Marshall R, Hemingway H, Myerson S, Clarkson P, Dollery C, Hayward M, Holliman DE, Jubb M, World M, Thomas EL, Brynes AE, Saeed N, Barnard M, Bell JD, Prasad K, Rayson M, Talmud PJ, and Humphries SE. Human gene for physical performance. Nature 393: 221-222, 1998[Medline].

25.   Montoye, HJ, and Gayle R. Familial relationships in maximal oxygen uptake. Hum Biol 50: 241-249, 1978[ISI][Medline].

26.   Myerson, S, Hemingway H, Budget R, Martin J, Humphries S, and Montgomery H. Human angiotensin I-converting enzyme gene and endurance performance. J Appl Physiol 87: 1313-1316, 1999[Abstract/Free Full Text].

27.   Palatini, P, Bongiovi S, Mario L, Mormino P, Raule G, and Pessina AC. Effects of ACE inhibition on endurance exercise haemodynamics in trained subjects with mild hypertension. Eur J Clin Pharmacol 48: 435-439, 1995[ISI][Medline].

28.   Predel, HG, Rohden C, Heine O, Prinz U, and Rost RE. ACE inhibition and physical exercise: studies on physical work capacity, energy metabolism, and maximum oxygen uptake in well-trained, healthy subjects. J Cardiovasc Pharmacol 23: S25-S28, 1994.

29.   Rankinen, T, Perusse L, Borecki I, Chagnon YC, Gagnon J, Leon AS, Skinner JS, Wilmore JH, Rao DC, and Bouchard C. The Na+-K+-ATPase alpha 2 gene and trainability of cardiorespiratory endurance: the HERITAGE Family Study. J Appl Physiol 88: 346-351, 2000[Abstract/Free Full Text].

30.   Rankinen, T, Perusse L, Gagnon J, Chagnon YC, Leon AS, Skinner JS, Wilmore JH, Rao DC, and Bouchard C. Angiotensin-converting enzyme ID polymorphism and trainability of the fitness phenotypes. the HERITAGE Family Study. J Appl Physiol 88: 1029-1035, 2000[Abstract/Free Full Text].

31.   Rauramaa, R, Rankinen T, Tuomainen P, Vaisanen S, and Mercuri M. Inverse relationship between cardiorespiratory fitness and carotid atherosclerosis. Atherosclerosis 112: 213-221, 1995[ISI][Medline].

32.   Rigat, B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, and Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86: 1343-1346, 1990.

33.   Rivera, MA, Dionne FT, Simoneau JA, Perusse L, Chagnon M, Chagnon Y, Gagnon J, Leon AS, Rao DC, Skinner JS, Wilmore JH, and Bouchard C. Muscle-specific creatine kinase gene polymorphism and VO2 max in the HERITAGE Family Study. Med Sci Sports Exerc 29: 1311-1317, 1997[ISI][Medline].

34.   Rivera, MA, Perusse L, Simoneau JA, Gagnon J, Dionne FT, Leon AS, Skinner JS, Wilmore JH, Province M, Rao DC, and Bouchard C. Linkage between a muscle-specific CK gene marker and VO2 max in the HERITAGE Family Study. Med Sci Sports Exerc 31: 698-701, 1999[ISI][Medline].

35.   Rupert, JL, Devine DV, Monsalve MV, and Hochachka PW. Angiotensin-converting enzyme (ACE) alleles in the Quechua, a high altitude South American native population. Ann Hum Biol 26: 375-380, 1999[ISI][Medline].

36.   Samani, NJ, Thompson JR, O'Toole L, Channer K, and Woods KL. A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation 94: 708-712, 1996[Abstract/Free Full Text].

37.   Sambrook, J, Fritsch EF, and Maniatis T. Molecular Cloning. Cold Spring Harbor, NY: Cold Spring Harbor, 1989.

38.   Schachter, F, Faure-Delanef L, Guenot F, Rouger H, Froguel P, Lesueur-Ginot L, and Cohen D. Genetic associations with human longevity at the APOE and ACE loci. Nat Genet 6: 29-32, 1994[ISI][Medline].

39.   Staessen, JA, Wang JG, Ginocchio G, Petrov V, Saavedra AP, Soubrier F, Vlietinck R, and Fagard R. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens 15: 1579-1592, 1997[ISI][Medline].

40.   Sundet, JM, Magnus P, and Tambs K. The heritability of maximal aerobic power: a study of Norwegian twins. Scand J Med Sci Sports 4: 181-185, 1994.

41.   Taylor, RR, Mamotte CD, Fallon K, and van Bockxmeer FM. Elite athletes and the gene for angiotensin-converting enzyme. J Appl Physiol 87: 1035-1037, 1999[Abstract/Free Full Text].

42.   Tiret, L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, and Soubrier F. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 51: 197-205, 1992[ISI][Medline].

43.   Ueda, S, Elliott HL, Morton JJ, and Connell JM. Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme. Hypertension 25: 1266-1269, 1995[Abstract/Free Full Text].

44.   Zee, RY, Ridker PM, Stampfer MJ, Hennekens CH, and Lindpaintner K. Prospective evaluation of the angiotensin-converting enzyme insertion/deletion polymorphism and the risk of stroke. Circulation 99: 340-343, 1999[Abstract/Free Full Text].


J APPL PHYSIOL 88(5):1571-1575
8570-7587/00 $5.00 Copyright © 2000 the American Physiological Society



This article has been cited by other articles:


Home page
J. Physiol.Home page
M. J. Joyner and E. F. Coyle
Endurance exercise performance: the physiology of champions
J. Physiol., January 1, 2008; 586(1): 35 - 44.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
C. Yamin, O. Amir, M. Sagiv, E. Attias, Y. Meckel, N. Eynon, M. Sagiv, and R. E. Amir
ACE ID genotype affects blood creatine kinase response to eccentric exercise
J Appl Physiol, December 1, 2007; 103(6): 2057 - 2061.
[Abstract] [Full Text] [PDF]


Home page
Exp PhysiolHome page
O. Amir, R. Amir, C. Yamin, E. Attias, N. Eynon, M. Sagiv, M. Sagiv, and Y. Meckel
Human, Environmental & Exercise: The ACE deletion allele is associated with Israeli elite endurance athletes
Exp Physiol, September 1, 2007; 92(5): 881 - 886.
[Abstract] [Full Text] [PDF]


Home page
ptjournalHome page
W. R Thompson and S. A Binder-Macleod
Association of Genetic Factors With Selected Measures of Physical Performance
Physical Therapy, April 1, 2006; 86(4): 585 - 591.
[Full Text] [PDF]


Home page
Br. J. Sports. Med.Home page
B Walpole, T D Noakes, M Collins, and R J Trent
Growth hormone 1 (GH1) gene and performance and post-race rectal temperature during the South African Ironman triathlon * Commentary
Br. J. Sports Med., February 1, 2006; 40(2): 145 - 150.
[Abstract] [Full Text] [PDF]


Home page
J. Gerontol. A Biol. Sci. Med. Sci.Home page
C. S. Carter, G. Onder, S. B. Kritchevsky, and M. Pahor
Angiotensin-Converting Enzyme Inhibition Intervention in Elderly Persons: Effects on Body Composition and Physical Performance
J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2005; 60(11): 1437 - 1446.
[Abstract] [Full Text] [PDF]


Home page
J. Gerontol. B Psychol. Sci. Soc. Sci.Home page
E. L. Grigorenko
The Inherent Complexities of Gene-Environment Interactions
J. Gerontol. B. Psychol. Sci. Soc. Sci., March 1, 2005; 60(suppl_Special_Issue_1): 53 - 64.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
A. G. Williams, S. S. Dhamrait, P. T. E. Wootton, S. H. Day, E. Hawe, J. R. Payne, S. G. Myerson, M. World, R. Budgett, S. E. Humphries, et al.
Bradykinin receptor gene variant and human physical performance
J Appl Physiol, March 1, 2004; 96(3): 938 - 942.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
L. Bahi, N. Koulmann, H. Sanchez, I. Momken, V. Veksler, A. X. Bigard, and R. Ventura-Clapier
Does ACE inhibition enhance endurance performance and muscle energy metabolism in rats?
J Appl Physiol, January 1, 2004; 96(1): 59 - 64.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
A. G. Williams, S. H. Day, S. Dhamrait ;, and R. M. Fuentes
ACE gene, physical activity, and physical fitness
J Appl Physiol, October 1, 2002; 93(4): 1561 - 1562.
[Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
R. M. Fuentes, M. Perola, A. Nissinen, and J. Tuomilehto
ACE gene and physical activity, blood pressure, and hypertension: a population study in Finland
J Appl Physiol, June 1, 2002; 92(6): 2508 - 2512.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
H. Montgomery, S. Dhamrait, J. R. Payne, A. Jones, D. Woods, L. A. Sonna, C. M. Lilly, M. A. Sharp, J. J. Knapik, and J. F. Patton
ACE Genotype and Performance
J Appl Physiol, April 1, 2002; 92(4): 1774 - 1777.
[Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
L. A. Sonna, M. A. Sharp, J. J. Knapik, M. Cullivan, K. C. Angel, J. F. Patton, and C. M. Lilly
Angiotensin-converting enzyme genotype and physical performance during US Army basic training
J Appl Physiol, September 1, 2001; 91(3): 1355 - 1363.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (64)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rankinen, T.
Right arrow Articles by Bouchard, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rankinen, T.
Right arrow Articles by Bouchard, C.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online